Livtencity
(Maribavir)ApprovedSmall molecule
TakedaLivtencity is a small molecule that works as a Phosphotransferase Pul97 Inhibitor; Serine/threonine-Protein Kinase BGLF4 Inhibitor.[2] It is being used across 5 indications, with its most advanced program in Approved.[1]
Livtencity is one of 95 small molecule programs targeting Viral Disease. It is currently in Approved.
5
Indications
18
Total Trials
5
Active Trials
94
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
121 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Livtencity
TakedaApproved
Ultomiris
AstraZenecaPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Felzartamab
BiogenPhase 3
Biological/vaccine
Vertex PharmaceuticalsPhase 3
Envarsus XR
UUniversity of Wisconsin, Madison
Phase 3
Cytogam
JJohns Hopkins University
Phase 3
Zemplar
AbbViePreclinical
Radicava
ShionogiPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cytomegalovirus (CMV) Infection3 trials
Cytomegalovirus (CMV)3 trials
Cytomegalovirus Infection2 trials
Adult2 trials
Hematopoietic Stem Cell Transplant (HSCT)1 trial
7 more indications
Kidney Transplant1 trial
Transplant Recipient1 trial
Oral1 trial
Liver Transplant1 trial
Pediatric1 trial
Regulatory
FDA Approval Timeline[4]
Nov 23, 2021
LIVTENCITY
NDA NDA215596
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Maribavir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]